Daicel Corporation Osteoclast Differentiation Inhibitor Urolithin EP3756664A1
Summary
The European Patent Office published patent application EP3756664A1 for Daicel Corporation on April 15, 2026, covering osteoclast differentiation inhibitor compositions containing urolithin. The inventors are KOBATA Kenji, NAKATANI Sachie, and KUDOH Masatake. The application is classified under A61K 31/37 (phthalide compounds) with designations covering 32 European states including DE, FR, GB, IT, and NL.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.
What changed
The EPO published patent application EP3756664A1 for Daicel Corporation, covering pharmaceutical compositions for inhibiting osteoclast differentiation using urolithin compounds. This publication makes the application publicly available and establishes priority dates for the claimed invention.
For companies developing urolithin-based therapeutics or bone-resorption inhibitors, this patent publication signals potential freedom-to-operate considerations in European markets. Generic pharmaceutical manufacturers and biotech firms researching ellagic acid derivatives should review the claim scope upon grant to assess potential licensing needs or design-around options.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
OSTEOCLAST DIFFERENTIATION INHIBITOR CONTAINING UROLITHIN
Publication EP3756664A1 Kind: A1 Apr 15, 2026
Applicants
Daicel Corporation
Inventors
KOBATA, Kenji, NAKATANI, Sachie, KUDOH, Masatake
IPC Classifications
A61K 31/37 20060101AFI20211021BHEP A23L 33/10 20160101ALI20211021BHEP A61P 19/08 20060101ALI20211021BHEP A61P 19/10 20060101ALI20211021BHEP A61P 43/00 20060101ALI20211021BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.